Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026)
Ultragenyx Pharmaceutical's (RARE) quarterly EBT Margin came in at 135.29% in Q1 2026, down 2738.0% year-on-year from 5.13% in Q1 2025, and down 130.46% on a QoQ basis from 58.71% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 11 years of EBT Margin data on file, last reported at 135.29% in Q1 2026.
- On a quarterly basis, EBT Margin fell 2738.0% year-over-year to 135.29% in Q1 2026; TTM through Mar 2026 was 89.48%, a 249.0% increase from a year earlier, with the FY2025 full-year figure at 83.95%, up 1658.0% from the prior year.
- EBT Margin for Q1 2026 stood at 135.29%, down from 58.71% in the prior quarter.
- Over the last five years, EBT Margin for RARE reached as high as 58.71% in Q4 2025 and fell as low as 263.3% in Q3 2022.
- Historically, EBT Margin has averaged 132.46% across 5 years, with a median of 135.29% in 2026.
- Across the five-year window, EBT Margin plunged 54750 bps in 2022 and soared 10114 bps in 2023, its largest moves.
- Year by year, EBT Margin stood at 148.32% in 2022, then jumped by 32 bps to 100.22% in 2023, then advanced by 22 bps to 78.24% in 2024, then advanced by 25 bps to 58.71% in 2025, then tumbled by 130 bps to 135.29% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 135.29% in Q1 2026, 58.71% in Q4 2025, and 112.26% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn | -135.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135.29% |
| Dec 31, 2025 | -58.71% |
| Sep 30, 2025 | -112.26% |
| Jun 30, 2025 | -68.47% |
| Mar 31, 2025 | -107.91% |
| Dec 31, 2024 | -78.24% |
| Sep 30, 2024 | -95.50% |
| Jun 30, 2024 | -88.92% |
| Mar 31, 2024 | -156.41% |
| Dec 31, 2023 | -100.22% |
| Sep 30, 2023 | -162.16% |
| Jun 30, 2023 | -146.89% |
| Mar 31, 2023 | -162.67% |
| Dec 31, 2022 | -148.32% |
| Sep 30, 2022 | -263.30% |
| Jun 30, 2022 | -176.69% |
| Mar 31, 2022 | -189.86% |
| Dec 31, 2021 | 399.18% |
| Sep 30, 2021 | -89.18% |
| Jun 30, 2021 | -140.23% |